Punit Dhillon
Chief Executive Officer & Director Skye Biosciences
Seminars
Thursday 16th April 2026
Maximizing Efficacy, Minimizing Risk by Leveraging Peripheral CB1 Antagonism in Combination with GLP-1 Agonists to Advance the Obesity Treatment Paradigm
1:30 pm
- Demonstrating the potential of combination therapy utilizing a peripherally acting CB1 antagonist (namacimab) with semaglutide, as evidenced by recent data showing enhanced weight loss and strong efficacy results
- Mitigating CNS-mediated side effects by focusing on peripheral CB1 receptors in adipose and muscle tissue, establishing a path for long-term patient comfort and adherence that is critical to redefining the patient journey
- Defining the strategy for next-generation metabolic therapeutics that layer novel mechanisms onto incretin backbones to provide superior clinical outcomes and establish a more robust, long-term safety profile
